ArticleClinical rheumatology2014
Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.
Article in Clinical rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.Annals of the rheumatic diseases · 2024Pooled it
- Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.Annals of the rheumatic diseases · 2020Trial
- The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still's disease.EULAR rheumatology open · 2026Article
- Review
- Tocilizumab discontinuation after remission achievement in patients with adult-onset Still's disease.Rheumatology (Oxford, England) · 2025Article
- Adult-onset Still's Disease (AOSD) with Gastrointestinal Lesions.Internal medicine (Tokyo, Japan) · 2024Article
- Adult-onset Still's disease masquerading as acute coronary syndrome: a case report and review of the literature.Journal of medical case reports · 2024Review
- Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts.Rheumatology (Oxford, England) · 2024Article
- Pyroptosis: the potential eye of the storm in adult-onset Still's disease.Inflammopharmacology · 2023Review
- Diagnosis and treatment of adult-onset Still's disease: a concise summary of the German society of rheumatology S2 guideline.Zeitschrift fur Rheumatologie · 2023Review
- The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.Clinical rheumatology · 2022Article
- Progress in Biological Therapies for Adult-Onset Still's Disease.Biologics : targets & therapy · 2022Review
- Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature.JAAD international · 2021Review
- Acute severe hepatitis in adult-onset Still's disease: case report and comprehensive review of a life-threatening manifestation.Clinical rheumatology · 2021Review
- Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.Rheumatology international · 2020Review
- Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still's Disease.Clinical reviews in allergy & immunology · 2020Review
- Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.Therapeutic advances in musculoskeletal disease · 2020Article
- Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.Rheumatology international · 2020Article
- Article
- Mechanisms, biomarkers and targets for adult-onset Still's disease.Nature reviews. Rheumatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset Still's disease (AOSD) is a chronic inflammatory disease of unknown etiology which commonly affects young adults. Treatment of AOSD patients includes nonsteroidal anti-inflammatory drugs, corticosteroids, and DMARDs. Interleukin (IL)-6 blockade is an attractive therapeutic option for AOSD because this cytokine contributes to the pathogenesis of major AOSD symptoms. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that blocks the effects of IL-6. Preliminary results of TCZ in AOSD have been promising. Here, we reported our experience evaluating both the safety and the efficacy of 12 months therapy with TCZ in 11 patients with AOSD refractory to corticosteroids and MTX therapy, followed for 18 months, including the first 12 months of active treatment and the last 6 months to evaluate the activity of the disease when the treatment was discontinued. The main outcome measures were the European League Against Rheumatism (EULAR) improvement criteria and improvement of systemic symptoms at the 3, 6, 12, and 18-months follow-up periods. Our patients rapidly responded and experienced a sustained clinical remission over time during active treatment. Disease Activity Score 28 decreased from 5.62 (3.75-8.28) [median (range)] at baseline to 1.61(0.49-3.5) at month 12. EULAR remission was achieved in 81.82 % at 12 months. Tender joint and swollen joint counts displayed a progressive reduction during active therapy study period. During treatment, we observed a resolution of fever in our AOSD patient. In conclusion, TCZ might represent a suitable option for the therapy of refractory AOSD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.